Diabetic Macular Edema Clinical Trial
Official title:
An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation
The development or worsening of macular edema following full scatter photocoagulation is a
well recognized occurrence. However, there is limited literature in this regard.
The purpose of this study is to determine the incidence and extent of macular edema
following scatter laser photocoagulation surgery using optical coherence tomography (OCT) in
eyes without macular edema prior to scatter laser photocoagulation and to explore whether
the incidence and extent of macular edema varies according to the number of sittings
included in the treatment regimen.
Study eyes will receive one of two types of scatter photocoagulation with results compared
through use of OCT and photography images, as well as visual acuity testing.
Study eyes will receive scatter photocoagulation given by one of the following two regimens.
To reduce selection bias, investigators will be required, prior to study initiation, to
indicate which treatment (1 PRP sitting or 4 PRP sittings) they will administer. Only the
selected treatment will be performed by a given investigator on study eyes.
- 1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width
separation of burns and scatter extending from the peripheral arcades to beyond the
equator.
- 4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in
each of the first two sittings and investigator judgment for number of burns for the
third and fourth sittings as long as the total for the four sittings is between 1200
and 1600 burns.
Both of these regimens conform with usual clinical practice.
The study aims to enroll 150 eyes. At least 40 eyes will be enrolled with prior focal laser
photocoagulation and at least 40 eyes without prior focal laser treatment. After enrollment
of 80 eyes (40 with prior treatment and 40 without prior treatment), an interim analysis
will be conducted so that focused enrollment strategies can be implemented if the analysis
suggests that more subjects in a subgroup should be entered. Approximately half of the eyes
will receive each scatter treatment regimen.
The following procedures will be done on the study eye at baseline and at each scheduled
visit (except 8 and 12 weeks at which exam data are not collected) unless otherwise
specified:
- OCT
- E-ETDRS visual acuity in both eyes (refraction in the study eye at baseline, 17 weeks,
and 34 weeks)
- Fundus photographs (7-fields at baseline and 3-fields at 34 weeks only)
- Photographs to document the scatter photocoagulation (day of the first PRP sitting
only)
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 |